Edge-to-Edge Tricuspid Valve Repair

C urrent transcatheter tricuspid valve (TV) device trials have been integral to our understanding of tricuspid regurgitation (TR) and right heart failure.Parikh et al. (1), in this issue of JACC: Case Reports, present a patient in whom a significant increased forward stroke volume (2.6 to 3.9 l/min/m 2 ) was accomplished with the off-label use of a mitral valve edge-to-edge device on the TV.Despite a seemingly modest reduction in TR from torrential to moderate-severe, the increase in cardiac index was associated with a significant clinical improvement both in hospital and at follow-up.The TriValve Registry showed that a reduction in TR to moderate using a variety of transcatheter devices was associated with clinical and functional benefits (2).Based on the early feasibility of the TRILUMI-NATE trial (Trial to Evaluate Treatment with Abbott Transcatheter Clip Repair System in Patients with Moderate or Greater Tricuspid Regurgitation) (3), the TriClip (Abbott Structural, Minneapolis, Minnesota) edge-to-edge repair system is the second Conformité Européene mark device to treat patients with severe TR and resistant right-sided heart failure.The